Comparison b/w Carbamazepine vs Oxcarbazepine in Treatment of Trigeminal Neuralgia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

122 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-20

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this Study investigator is comparing the effectiveness and outcomes of two drugs used un the treatment of trigeminal neuralgia , Carbamazepine vs Oxcarbazepine

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia

NCT06849219

Trigeminal Neuralgia

ACTIVE_NOT_RECRUITING PHASE4

Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical Trial

NCT04996199

Trigeminal Neuralgia

UNKNOWN PHASE4

Pregabalin as an add-on Therapy to Carbamazepine in Trigeminal Neuralgia Patients

NCT06357260

Trigeminal Neuralgia

RECRUITING NA

Nucleo CMP and Neurorubine Versus Carbamazepine for Classical Trigeminal Neuralgia

NCT07304453

Trigeminal Neuralgia Neuropathic Pain

COMPLETED PHASE2

Phenytoin as Treatment for Acute Exacerbations of Trigeminal Neuralgia - a Prospective Systematic Study of 20 Patients

NCT03712254

Trigeminal Neuralgia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this open pilot open label randomized controlled trial, Investigator is comparing the effectiveness and outcomes of two drugs used un the treatment of trigeminal neuralgia, Carbamazepine vs Oxcarbazepine , hypothesis would be that oxcarbazepine has equal or better outcomes comparatively with less side effects

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Trigeminal Neuralgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Carbamazepine group

In this group participants has been prescribed with carbamazepine which is conventional drug for trigeminal neuralgia management

Group Type ACTIVE_COMPARATOR

Carbamazepine

Intervention Type DRUG

Carbamazepine is a conventional drug used to treat trigeminal neuralgia. It primarily works by blocking voltage-gated sodium channels in nerve cells, which prevents rapid and repetitive firing of action potentials and reduces abnormal electrical activity in the brain.

Oxcarbazepine group

In this group participants has been prescribed with oxcarbazepine which is new FDA approved drug for TGN management

Group Type ACTIVE_COMPARATOR

oxcarbazepine

Intervention Type DRUG

Oxcarbazepine is comparatively new approved drug in the treatment of TGN. Oxcarbazepine is a prodrug that is rapidly converted to its active metabolite, (monohydroxy metabolite or MHD). This active form works by blocking voltage-sensitive sodium channels in the brain, which stabilizes over-excited nerve membranes and prevents the rapid spread of abnormal electrical activity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carbamazepine

Carbamazepine is a conventional drug used to treat trigeminal neuralgia. It primarily works by blocking voltage-gated sodium channels in nerve cells, which prevents rapid and repetitive firing of action potentials and reduces abnormal electrical activity in the brain.

Intervention Type DRUG

oxcarbazepine

Oxcarbazepine is comparatively new approved drug in the treatment of TGN. Oxcarbazepine is a prodrug that is rapidly converted to its active metabolite, (monohydroxy metabolite or MHD). This active form works by blocking voltage-sensitive sodium channels in the brain, which stabilizes over-excited nerve membranes and prevents the rapid spread of abnormal electrical activity

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-60 years
* Either gender
* TGN diagnosis for ≥2 weeks (according to ICHD-3 criteria¹)

Exclusion Criteria

* Other cranial neuralgias
* Prior surgical treatment for TN
* Hepatic/renal dysfunction
* Epilepsy
* Pregnant/lactating women
* Drug allergy or intolerance
* \[Expanded\] Uncontrolled hypertension
* \[Expanded\] Psychiatric disorders

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No